Advertisement


Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy

2017 Multidisciplinary Thoracic Cancers Symposium

Advertisement

Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.



Related Videos

Lung Cancer

Boris Sepesi, MD, on NSCLC, TILs, and Overall Survival

Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).

Lung Cancer

Zhongxing Liao, MD, on Proton-Beam Radiotherapy for Locally Advanced Disease

Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce radiation exposure and increase tumor dose.

Lung Cancer

Kamran Ahmed, MD, on Lung Cancer, Radiation, and Immune Checkpoint Inhibitors

Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti–PD-1 therapy, anti–PD-L1 therapy, anti–CTLA-4 therapy, or some combination of these drugs (Abstract 10).

Lung Cancer

Jennifer Ho, MD, on Thoracic Cancers: Reirradiation With IMPT

Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity in patients who can have extended survivals; the data also suggest that higher doses may improve outcomes (Abstract 5).

Lung Cancer

Maximilian Diehn, MD, PhD, on Liquid Biopsies/Cell-Free DNA: Clinical Uses

Maximilian Diehn, MD, PhD, of Stanford School of Medicine, discusses promising clinical applications of circulating tumor DNA in patients with thoracic malignancies: noninvasive detection of resistance mechanisms to targeted agents and treatment response assessment.

Advertisement

Advertisement




Advertisement